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Abstract.  ADP-ribosylation factor (ARF) proteins and 
inhibitory peptides derived from ARFs have demon- 
strated activities in a number of in vitro assays that 
measure ER-to-Golgi and intra-Golgi transport and en- 
dosome fusion.  To better understand the roles of ARF 
proteins in vivo, stable cell lines were obtained from 
normal rat kidney (NRK) cells transfected with either 
wild-type or a dominant activating allele ([Q71L])  of 
the human ARF1 gene under the control of the 
interferon-inducible mouse Mxl promoter.  Upon addi- 
tion of interferon,  expression of ARF1 proteins in- 
creased with a half-time of 7-8 h,  as determined by 
immunoblot analysis.  Induction of mutant ARF1, but 
not wild-type ARF1, led to an inhibition of protein 
secretion with kinetics similar to that observed for in- 
duction of protein expression.  Examination of the 
Golgi apparatus and the ER by indirect immuno- 
fluorescence or transmission  electron microscopy 
revealed that expression of low levels of mutant ARF1 
protein correlated with a dramatic increase in vesicula- 
tion of the Golgi apparatus and expansion of the ER 
lumen,  while expression of substantially higher levels 
of wild-type ARF1 had no discernible effect. Endocy- 
tosis was also inhibited by expression of mutant 
ARF1, but not by the wild-type protein.  Finally, the 
expression of [Q71L]ARF1,  but not wild-type ARF1, 
antagonized the actions of brefeldin A, as determined 
by the delayed loss of ARF and B-COP from Golgi 
membranes and disruption of the Golgi apparatus. 
General models for the actions of ARF1 in membrane 
traffic events are discussed, 
P-ribosylation factors (ARFs)  t are a family of small 
(21 kD) GTP-binding  proteins.  ARF was first iden- 
tiffed as the protein eofactor required for efficient 
ADP-ribosylation of the stimulatory regulatory subunit  of 
adenylate  cyclase, Gs, by cholera toxin (Kahn and Gilman, 
1984,  1986;  Kahn,  1989).  The ARF family  consists  of at 
least 15 structurally  related human gene products including 
the functionally  distinct ARF and ARF-like (ARL) proteins 
(Clark et al., 1993). At least one member of each subfamily 
is essential  for survival;  ARF genes in yeast (Stearns et al., 
1990a)  and arl in Drosophila (Tamkun et al.,  1991). ARF 
proteins  are  ubiquitous  in  eukaryotic cells  (Kahn  et  al., 
1988). The ARF family is one of four families in the RAS 
superfamily  based on similarities  in molecular weight and 
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presumptive mechanisms  of regulation.  However, the ARF 
proteins exhibit  a similar  degree of homology to members 
of both the RAS superfamily  and the heterotrimeric G pro- 
tein  family  (Sewell  and Kahn,  1988).  The  structural  and 
functional  conservation  between ARF proteins of divergent 
species (Sewell and Kahn,  1988; Kahn et al., 1991) suggests 
fundamental  roles for ARF in cellular physiology. 
ARF proteins are thought  to participate  in a number of 
membrane traffic events. ARFs may regulate traffic through 
the secretory pathway, based on both genetic (Stearns et al., 
1990b) and biochemical data, employing  in vitro assays of 
protein transport (Balch et al., 1992; Kahn et al., 1992; Len- 
hard et al., 1992). Previous studies have also demonstrated 
that  ARF is associated with Golgi membranes (Stearns  et 
al., 1990b; Donaldson et al., 1991) and Golgi-derived COP- 
coated vesicles (Serafini  et al.,  1991). ARF proteins also 
modulate endosome-endosome fusion in vitro (Lenhard  et 
al., 1992) and nuclear membrane fusion in Xenopus egg ex- 
tracts (Boman et al., 1992). Despite this wealth of informa- 
tion with regard  to the in vitro biochemical properties of 
ARF protein family members, the relationship between these 
orooerties and in vivo function of ARF proteins remains un- 
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family in each of these in vitro assays has been difficult to 
ascertain due to the presence of multiple gene products in 
purified ARF preparations and the extent of structural relat- 
edness among these gene products. 
A common feature of all GTP-binding proteins, including 
ARFs,  is the regulated  binding  and hydrolysis of guanine 
nucleotides which serve as molecular switches in signaling 
pathways. Replacement of the glutamine residue in the con- 
sensus  sequence,  DXXGQ,  with  leucine  impairs  intrinsic 
GTP hydrolysis by members of both the G protein (Graziano 
and Gilman,  1989; Masters et ai.,  1989) and RAS (Vogel et 
al.,  1988; Gideon et al.,  1992) superfarnilies.  Expression of 
such mutants has provided insights into regulatory functions 
of these proteins,  including their potential role(s) in onco- 
genesis (Barbacid,  1987;  Landis et ai.,  1989). 
ARF proteins are myristoylated in vivo and the cellular ac- 
tions of ARF proteins involve the reversible association with 
specific intracellular  membranes  in myristoylation-depen- 
dent and  guanine  nucleotide-regulated  reactions  (Balch et 
al.,  1992; Donaldson et al.,  1992a; Kahn et al.,  1992; Len- 
hard et al., 1992). Binding of the activating nucleotide, GTP, 
results in a conformational change in the protein (Kahn and 
Gilman,  1986) and an increased affinity for phospholipids 
and  membranes  (Donaldson  et  al.,  1991;  Regazzi  et al., 
1991; Randazzo et al.,  1993). The inactive GDP-bound form 
of ARF is  soluble  (Weiss  et al.,  1989;  Randazzo  et al., 
1993).  Recent  work from  our  laboratory  and  others  has 
documented  the  presence  of  an  ARF-activating  protein 
(AAP) in crude Golgi fractions that is sensitive to the fungal 
metabolite,  brefeldin  A  (BFA)  (Donaldson  et al.,  1992b; 
Helms and Rothman, 1992; Randazzo et ai., 1993). Addition 
of BFA to normal rat kidney (NRK) cells results in the rapid 
dissociation of ARF and t-COP from the Golgi and subse- 
quent fusion of Golgi elements with the ER (Donaldson et 
al.,  1990,  1991;  Lippincott-Schwartz  et  ai.,  1991).  BFA 
affects the organization  of the Golgi apparatus  in a variety 
of cells in culture and also has effects on endosome recycling 
(Lippincott-Schwartz et al., 1989; Wood et ai.,  1991), trans- 
cytosis (Hunziker et al.,  1991),  and cell proliferation  in a 
number of human tumor cell lines (for a recent review of the 
effects of BFA, see Klausner et al.,  1992). 
To define more clearly  the physiological  role(s)  of one 
member of the ARF family, we produced stably transfected 
cell lines carrying either wild-type ARF1 or the dominant ac- 
tivating  mutant  of human  ARFI,  [Q71L]ARF1,  under  the 
control of the tightly regulated mouse Mxl promoter (Hug 
et al., 1988; Arnheiter et al., 1990). The results suggest that 
expression of mutant ARF1, but not wild-type ARF1 protein, 
has distinct effects on the structure and/or function of ER, 
Golgi apparatus, and endocytic pathway in mammalian cells. 
Materials and Methods 
Construction of  Plasmids 
Vector pSS2-2  was constructed by ligation of the 2.5-kb EcoRI-BamHI 
fragment of the mouse Mxl  upstream regulatory  sequence (Hug et al., 
1988) and a 1.5-kb BamHI-XbaI fragment of the mouse/~-globin gene (in- 
cluding a noncoding part of exon 2, intron 2, and noncoding exon 3 contain- 
ing the poly A site) into the polylinker region of Sp65. The entire coding 
region and ',,50 bp of the 5' untranslated region of wild-type or mutant hu- 
man ARF1 was inserted at the BamHI site, which corresponds to the start 
site of transcription. The resulting plasmids are referred to as pZCld (wild- 
type ARF1) and pZC1-3 (mutant ARF1). The mutant ARF was produced by 
oligonucleotide-directed PCR mutagenesis. Sequencing of the original mu- 
tant revealed two mutations resulting in two changes in amino acid  se- 
quence:  [K38R]  introduced by Taq polymerase  error and [Q71L]  as de- 
signed into the oligonucleotide primers. Much of the data shown here were 
obtained using this double mutant. We have subsequently constructed two 
independently isolated cell lines capable of expressing the single mutant, 
[Q71L]ARF1,  and confirmed that all of the effects described result from this 
single point mutation. 
Cells and Cell Culture 
NRK cells were obtained from American Type Culture Collection (ATCC, 
Rockville, MD) and grown and passaged in RPMI 1640 medium (GIBCO 
BRL,  Gaithersburg,  MD)  containing  10%  fetal  bovine serum  (GIBCO 
BRL) at 37°C in a humidified atmosphere containing 5% CO2. Cells were 
cotransfected with either pSS2-2, pZCI-1, or pZC1-3 and pSV2-neo (carry- 
ing the selectable marker for resistance to neomycin [G418]; ATCC) at a 
ratio of 10:1  with lipofectin (GIBCO BRL), according to manufacturer's 
specifications. Selection and cloning of stable transfectants was performed 
as previously described (Southern and Berg, 1982). The cell lines used in 
this study were ZCI-OB  (transfected with pSS2-2-1acking insert), ZCI-IA 
(transfected with the plasmid allowing inducible expression of wild-type 
ARFI), and ZC1-3B (transfected with the plasmid allowing inducible ex- 
pression of [Q71L]ARF1).  Induction of ARF expression was performed by 
incubating cells in medium containing 1,000 U/ml a/# rat interferon (Lee 
Biomolecular,  San Diego,  CA) for up to 24 h. 
Microscopy 
For indirect immunofluorescence microscopy, cells were grown on 10-ram 
glass coverslips for 24-48 h before induction with interferon. Cells were 
fixed and stained as previously described (Stearns et al., 1990b) with either 
a mouse monoclonal anti-ARF antibody (ID9, 13 #g/mi), a polyclonal rab- 
bit anti-c~-mannosidase II antibody (gift of Drs. Marilyn Farquhar [Univer- 
sity of California, Los Angeles, CAI and Kelley Moremen [University of 
Georgia, Athens, GA]) (Moremen et al.,  1991),  a monoclonal anti-protein 
disulfide isomerase (PDI) antibody (gift of Dr. Jane Cheng [Laboratory of 
Molecular Biology, National Cancer Institute, National Institutes of Health, 
Bethesda, MDI) (Hasamura et al., 1986), or a polyclonal rabbit anti-E-COP 
peptide antibody (gift of Dr. Jennifer Lippincott-Schwartz, National Insti- 
tute  of Child  Health  and  Human  Development,  National  Institutes  of 
Health), followed by the appropriate fluorescein isothiocyanate-conjugated 
secondary antibody (Cappel Labs, Durham, NC). For vital staining, cells 
were grown on 25-ram glass coverslips for 24-48 h before interferon induc- 
tion, then stained with the Golgi marker, C6-NBD-ceramide (Lipsky and 
Pagano,  1983),  as previously described  (Rosenwald et al.,  1992).  Pho- 
tomicrographs were obtained with a Olympus IMT-2 microscope equipped 
with a  100x  lens. 
For phase contrast microscopy, cells grown on coverslips were fixed as 
described (Stearns et al.,  1990b) and visualized after treatment with tolu- 
idine blue. 
Transmission electron microscopy  was performed as described previ- 
ously (Stearns et al.,  1990b). 
Miscellaneous 
Immunoblotting was  performed  on NRK  cell  lysates  as  previously  de- 
scribed (Kahn et al., 1988). Briefly, 15-30 #g protein from total cell lysates 
was  separated by electrophoresis in a  10--20%  acrylamide gradient gel, 
prior to electrophoretic transfer to nitrocellulose. Two ARF antibodies were 
used in these studies.  The monoclonal antibody,  1Dg,  was purified from 
mouse ascites and used as primary antibody at 1-10 #g/ml.  1D9 is an IgGl 
with specificity for mammalian ARFs 1, 3, 5, and 6. It can detect as little 
as 0.1 rig ARF per lane but does not bind mammalian ARL proteins (1-3), 
or yeast ARFs and detects mammalian ARF4 only poorly ('~50-fold less 
reactive than other ARFs). A rabbit polyclonal, No.  1026,  was generated 
against a  COOH-terminai peptide derived from ARF1.  It has very good 
specificity for ARF1, and fails to detect ARF3-6 or ARL1-3  (Cavenagh, 
M., K. Carroll, and R. A. Kahn, unpublished observation). The rabbit se- 
rum is used at a 1/1,000 dilution. Details of the production and specificity 
of these and other ARF antibodies will be found in Cavenagh, et al. (manu- 
script in preparation), 
To analyze the effect of ARF1 induction on protein secretion, cells grown 
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U/ml a//~ rat interferon for up to 24 h. The monolayers were then washed 
once with Dulbecco's minimal essential media lacking methionine, and in- 
cubated in  medium containing 5  #Ci/ml  [3~S]methionine  (cell labeling 
grade, >1,000 Ci/mmol; Amersham, Arlington Heights, IL) (1 #g/ml final 
methionine concentration) and 0.5%  fetal bovine serum for 3 h  at 370C. 
Labeling medium was removed and labeled secreted proteins were precipi- 
tated by incubation at 4°C for 30 rain after the addition of sodium dodecyl 
sulfate (0.5% final concentration), bovine serum albumin (50 #g/ml final 
concentration), cold methionine (750 #g/ml final concentration), and tri- 
chloroacetic acid (10% final concentration). Precipitates were collected on 
nitrocellulose filters and washed four times with ice-cold 10 % trichloroace- 
tic acid. Filters were allowed to air dry overnight before addition of  scintilla- 
tion fluid. Labeling medium that had not been incubated with cells was sub- 
jected to the same precipitation to determine background.  Labeled cells 
were scraped from the dish in 1 ml cold phosphate-buffered saline and sub- 
jected to precipitation with trichloroacetic acid as for medium samples. 
The uptake of HRP was determined as previously described (Marsh et 
al., 1987; Bucci et al., 1992). Briefly, cells grown on 60-mm culture dishes 
treated with or without interferon were incubated with RPMI 1640 medium 
(serum free) containing 5 mg/ml HRP (type II; Sigma Chemical Co., St. 
Louis, MO) and 0.1% bovine serum albumin for 60 rain. Uptake of HRP 
was linear  with time.  The monolayers were then washed with ice-cold 
Ca  2+- and Mg2+-free phosphate-buffered saline containing 0.1% bovine se- 
rum albumin.  The cells were scraped from the dish and washed several 
times. Cell lysates were prepared by resuspension in 10 mM Hepes, pH 7.4, 
0.2% Triton X-100 followed by multiple passages through a 21-gauge  nee- 
dle. The lysate was centrifuged at 800 g for 10 min and the supernatant was 
used to determine protein concentration and HRP activity. 
Results 
Induction of  ARF1 Expression by Addition 
of Interferon 
To study the consequences of  the overexpression  of wild-type 
ARF1 and the expression of  a potentially lethal, dominant al- 
lele of ARF1, we created stable cell lines carrying ARF con- 
structs under control of an inducible but tightly regulated 
promoter, the mouse Mxl promoter (Hug et al., 1988). The 
stable cell lines ZC1-0B, ZCI-IA, and ZC1-3B, that carry the 
parent vector, the vector containing wild-type ARF1, and the 
vector containing mutant ARF1, respectively, were made as 
described in Materials and Methods. These cell lines have 
been growing in continuous culture in the absence of inducer 
for more than three months. 
Addition of interferon did not alter either the growth rate 
(doubling  time  =  17  h)  or  morphology of untransfected 
NRK cells, cells containing the parent vector, or cells ex- 
pressing  wild-type ARF1,  In  contrast,  the growth  rate of 
ZC1-3B  cells,  containing the inducible mutant ARF1  con- 
struct, was slightly slower than controls (doubling time  = 
20 h) in the absence of interferon, and proliferation was com- 
pletely blocked in the presence of interferon. Cell rounding 
was first observed in ZC1-3B cells after 24 h of induction and 
by 2-3  d  most cells had detached from the culture dish. 
Those cells remaining adherent were filled with large vesi- 
cles or vacuoles. 
The levels of  ARF proteins expressed in the cell lines were 
estimated by quantitative immunoblotting of  cell lysates with 
a monoclonal anti-ARF antibody (Fig. 1 A) and with a semi- 
quantitative, polyclonal anti-ARFl-specific antiserum (Fig. 1 
B).  Control cells express endogenous ARF1  to a  level of 
~0.03-0.1% of total NRK cell protein. ARF1 and ARF3 are 
the major forms of ARF  found in NRK cells and are ex- 
pressed at similar levels while ARF4-6 are below the limits 
of detection for our antibodies. Thus, endogenous ARF1  is 
Figure 1. Time course of induction of ARFI proteins after addition 
of interferon. (A) NRK (diamonds), ZC1-0B (vector control, trian- 
gles), ZC1-3B (mutant ARFI, squares), or ZCI-IA cells (wild-type 
ARF1, circles) were incubated with interferon and lysates were sub- 
jected to quantitative immunoblot analysis using the monoclonal 
ARF antibody, 1D9, and radioiodinated reporter, as described in 
Materials and Methods. Quantitation was performed using a Phos- 
phorlmager. This experiment was repeated at least five times with 
similar results. (B) The same three stably transfected cell lines were 
incubated for various times with interferon and the level of ARF1 
expression was assessed using the ARFl-specific polyclonal rabbit 
antiserum, No. 1026. Purified recombinant ARF1 and ARF3 pro- 
teins (25 ng each) were included as controls for specificity. Im- 
munoreactivity was visualized by chemiluminescence, as described 
in Materials and Methods. 
approximately half of the ARF expressed in control cells. 
Addition of 1,000  U/ml  cz//3 rat interferon led to a  time- 
dependent increase in the level of ARF1  expressed in the 
transfectants  (ZCI-1A;  Fig.  1,  circles)  but no  statistically 
significant change in ARF levels in controls lacking an in- 
ducible ARF construct (NRK and ZC1-0B)  or in ZC1-3B. 
The level of expression for at least two independent isolates 
of each construct was 200-300% (n =  8) and 0-25 % (n = 
5; not significantly different from controls) of total endoge- 
nous ARF proteins for wild-type and mutant ARF1, respec- 
tively (Fig.  1 A).  We also determined the time course of 
protein  induction  using  a  specific,  polyclonal,  anti-ARF1 
antibody (Fig.  1 B).  This antiserum has  about a  10-fold 
lower affinity for ARF1  but a  much greater specificity for 
ARF1  than does the monoclonal. Visualization of ARF1 ex- 
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quired the use  of a  chemiluminescence detection system 
which is less quantifiable than using radioiodinated second- 
ary or tertiary antibodies. We have found about a 10-fold in- 
crease  in  sensitivity in the chemiluminescence technique 
over radioiodine detection. Results obtained with the ARF1- 
specific antibody confirm that the wild-type protein is in- 
duced with a half-time of ,,07-8 h while induction of the mu- 
tant ARF1 takes slightly longer (,,o10 h). Maximal levels of 
each ARF1 protein were achieved by 12-16  h. 
Taken together, we estimate that wild-type ARF1  is in- 
duced to a level of 500-600% of endogenous ARF1 and the 
ARFI mutant is expressed to 50-100% the level of endoge- 
nous ARF1. This has proven to be a consistent finding. Mu- 
tants of ARF proteins are expressed at lower levels than their 
wild-type counterparts. The reason for this is unclear but 
may reflect decreased protein half-lives, interference by mu- 
tant ARFs with the interferon signaling pathway, or currently 
unknown consequence of dominant mutant ARF expression. 
It is not a result of inhibition of general protein synthesis (see 
below). 
Expression of  Mutant ARF1 Inhibits 
Protein Secretion 
ARF proteins have been shown to be involved in vesicular 
traffic through the Golgi apparatus (Donaldson et al., 1991; 
Serafini et al., 1991; Kahn et al., 1992).  To ask if ARF ex- 
pression affected vesicular traffic, we analyzed protein secre- 
tion from cells after induction of  wild-type and mutant ARFI 
(Fig. 2). We found that upon addition of interferon, there was 
a  time-dependent inhibition of protein secretion, but only 
from cells expressing  the  mutant ARF1  protein  (Fig.  2, 
squares), not from cells expressing wild-type ARF1 protein 
(Fig. 2, circles). The half-time for inhibition of secretion was 
similar to that observed for induction of ARF1 protein ex- 
pression as determined by immunoblot analysis (see Fig. 1). 
Induced ZCI-IA cells, expressing higher levels of wild-type 
ARF1, were consistently found to have higher rates of pro- 
tein secretion than controls, but the magnitude of this effect 
was small and not statistically significant. 
Expression of  [Q71L]ARF1 Alters the Morphology of 
SubceUular OrganeUes 
We next examined the location of ARF protein in induced 
and uninduced cells by immunofluorescence microscopy. 
Immunolocalization of ARF in control or induced cultures 
of ZCI-0B (Fig. 3, A and B) or ZCI-IA (Fig. 3,  C and D) 
cells, or uninduced ZC1-3B cells (Fig. 3, E) revealed a pre- 
dominant perinuclear localization, as previously described 
for ARF in NIH 3T3 (Steams et al., 1990b),  human adrenal 
carcinoma (Steams et al., 1990b),  and NRK (Donaldson et 
al., 1991) cells. Induction of [Q71L]ARF1 protein expression 
in ZC1-3B cells caused a dramatic increase in the intensity 
of the perinuclear staining observed with ARF antibodies 
(Fig.  3,  F)  and the compartment stained was  noticeably 
larger than that seen in control cells. 
As it is known that ARF binds reversibly to Golgi mem- 
branes (Stearns et al.,  1990b;  Donaldson et al.,  1991), we 
next determined that the increase in perinuclear staining in 
induced ZC1-3B cells reflected changes in the morphology 
of the Golgi apparatus itself. Immunofluorescence staining 
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Figure 2.  Effect  of ARFI expression on secretion of [35S]methi- 
onine-labcled proteins from cells. ZCI-IA (wild-type ARFI, cir- 
cles) and ZC1-3B (mutant ARF1, squares ) cells were incubated 
with or without interferon for up to 24 h, then with [35S]methio- 
nine as described in Materials and Methods. Proteins recovered 
in the medium  were precipitated with trichloroacetic acid and 
counted. Data is expressed as the  percentage of  counts secreted  in 
the  presence of  interferon  relative  to  counts secreted  in  the  absence 
of interferon  (average of 3 determinations). 
patterns  for  the  lumenal  Golgi  protein,  mannosidase  II 
(Moremen et al., 1991) (Fig. 4, C-F) were very similar to 
those observed with the ARF antibody in ZCI-IA and ZC1- 
3B (compare to Fig. 3). C6-NBD-ceramide, a vital stain for 
the Golgi apparatus (Lipsky and Pagano, 1983; Rosenwald 
et al.,  1992),  also  labeled a  dramatically increased area 
around the nucleus in induced ZC1-3B cells (Fig. 4, compare 
A and B). This increase in Golgi staining in both living and 
fixed cells was often manifested as a  perinuclear "collar: 
Staining of all control cells (including NRK, ZC1-0B, and 
ZCI-IA cells treated with or without interferon and ZC1-3B 
without interferon induction) with these same probes did not 
reveal any alterations in the typical perinuclear staining pat- 
tern (Fig. 4, A and C-E; and data not shown). The time re- 
quired to observe changes in morphology of the Golgi ap- 
paratus  in  ZC1-3B  cells  paralleled  the  time  course  of 
induction of ARF1  expression after addition of interferon 
(data not shown). 
The morphological changes resulting from the expression 
of mutant ARF1 were also evident in toluidine blue-stained 
phase contrast images of living or fixed cells (Fig. 5, com- 
pare A and B). Time-lapse photomicroscopy of phase con- 
trast images of induced ZC1-3B cells also revealed a close 
correlation between the time course of induction of mutant 
protein and changes in Golgi morphology (data not shown). 
When ZC1-3B cells were viewed using transmission electron 
microscopy, extensive profusion and vesiculation of mem- 
branes in the Golgi region and loss of normal Golgi elements 
were apparent in induced ZC1-3B cells (Fig. 5 D) but not in 
induced ZC1-0B (Fig. 5 C) or any of the other control cells 
(data not shown). 
In addition to the obvious changes in the structure of the 
Golgi apparatus, substantial changes in the ER of induced 
ZC1-3B cells were also observed. By electron microscopy, 
the ER, which could be identified by the presence of bound 
The Journal of  Cell Biology, Volume 124, 1994  292 Figure 3.  [Q71L]ARF1 expression leads to a nuclear collar of ARF staining. The location of ARF proteins in uninduced (A, C, and E) 
or interferon-induced (B, D, and F) cultures of ZC1-0B (A and B vector control), ZCI-IA (C and D, wild-type ARF1), and ZC1-3B (E 
and F mutant ARF1) was determined by indirect immunofluorescence microscopy as described in Materials and Methods. Cells were in- 
cubated with interferon for 18 h. Note the presence of the perinuclear collar in E 
ribosomes,  appeared swollen (Fig.  5  D).  The altered ER 
structure was quite large in some cases and was occasionally 
seen to surround other organelles,  such as mitochondria. 
The ER ofuninduced ZC1-3B or ZC1-0B cells (Fig. 5 C) was 
indistinguishable from controls. 
The observed change in ER morphology prompted an ex- 
amination of the immunolocalization of the ER resident pro- 
tein disulfide isomerase (Hasamura et al., 1986). Typical re- 
titular morphology was seen throughout the cytosol in all 
control cells (Fig. 4  G) (data not shown). Induced ZC1-3B 
cells also showed staining in the cytosol but staining was 
specifically excluded from the Golgi-derived collar (Fig. 4 
H). Thus, these two compartments remained clearly distinct 
in cells which express the mutant ARF protein,  although 
changes in the morphology of both the ER and the Golgi ap- 
paratus were apparent by EM. 
Zhang et al. Effects of Mutant ARF1 Expression  293 Figure 4.  Effect of ARFI expression on morphologies of the Golgi apparatus and the ER.  The distribution of the vital Golgi stain Ca- 
NBD-ceramide (.4 and B), the lumenal Golgi protein mannosidase 1I (C-F), and the ER marker, protein disulfide isomerase (G and H) 
are shown for ZCI-IA (C and D, wild-type ARF1) and ZCI-3B (A, B, and E-H, mutant ARF1) cells. Fluorescence images from cells grown 
in the absence (A, C, E, and G) or presence (B, D, F, and H) of interferon for 18 h are shown. Ordy ZCb3B (mutant ARF1) cells grown 
in the presence of interferon show alterations at the Golgi apparatus. 
The Journal of Cell Biology,  Volume 124, 1994  294 Figure 5. Morphological changes at the ER and Golgi apparatus  visualized  by phase contrast and transmission electron microscopy. Phase 
contrast images oftoluidine blue-stained fixed ZC1-3B (mutant ARF1) cells in the absence (A) or presence (B) of  interferon for 18 h. ZC1-3B 
cells show extensive enlargement in and vesiculation  of the Golgi (B, arrows). Transmission  EM images are shown of ZC1-0B (C, vector 
control) and ZCI-3B (D, mutant ARF1) cells treated with interferon.  Induced ZC1-3B cells (D) show extensive vesiculation  of membranes 
in the Golgi region (arrows), loss of normal Golgi elements,  and swelling of the ER. G, Golgi apparatus;  er, endoplasmic reticulum;  N, 
nucleus; m, mitochondrion; Ly,  lysosome). Bars:  (A and B) 7 #m; (C) 0.4 #m; (D) 0.2/~m. 
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Fluid-phase Endocytosis 
Previous work has demonstrated that ARF proteins, in addi- 
tion to their role(s) in traffic through the secretory pathway, 
also participate in endosome-endosome fusion reactions in 
vitro (Lenhard et al., 1992). Therefore, we next determined 
the effect of ARF1 expression on uptake of the fluid-phase 
marker, HRP (Fig. 6). Expression of mutant ARF1 protein 
(Fig. 6, circles)  inhibited fluid-phase endocytosis, but not 
wild-type ARF1 protein (Fig. 6, squares),  or vector control 
(ZC1-0B, Fig. 6, triangles).  The time required for inhibition 
paralleled that required for induction of ARF1 expression by 
interferon. The uptake of HRP was linear for up to 60 min 
in these experiments and inhibition was observed as early as 
2.5 min after addition of HRP to previously induced cells 
(data not shown). 
Effect of ARF1 Expression on BFA Activity 
Incubation of cells with the fungal metabolite, BFA, causes 
disruption of the Golgi apparatus (Lippincott-Schwartz et 
al., 1991). This is preceded by release of ARF and/~-COP 
proteins from the Golgi membranes (Donaldson et al., 1991, 
1992a).  Previous work from our laboratory (Randazzo et 
al., 1993) and others (Donaldson et al., 1992b;  Helms and 
Rothman,  1992)  has  shown that AAP,  present  on  Golgi 
membranes, is sensitive to BFA.  This suggests that BFA, 
which inhibits activation of ARF proteins, and the [Q71L]- 
ARF1  mutant, which is predicted to lack GTPase activity 
and promote the active form of ARF1, should act antagonisti- 
cally. Therefore, we next determined the effect of mutant and 
wild-type ARF1 expression on the ability of BFA to release 
/3-COP from the Golgi apparatus (Fig. 7). Expression of  mu- 
tant ARF1 protein, but not wild-type ARF1 protein, delayed 
the BFA-induced release of/3-COP. The BFA-induced release 
of ARF from Golgi structures was also delayed in cells ex- 
pressing the mutant ARF protein (data not shown). It should 
be noted that expression of mutant ARF1 caused expansion 
of the Golgi compartment, but did not lead to mixing of the 
Golgi and ER compartments (Fig. 4), as is typically seen 
upon addition of BFA to cells. Thus it appears that the ex- 
pression of [Q71L]ARF1  was  antagonistic to the  activity 
of BFA. 
Discussion 
We demonstrated that expression of a dominant allele of hu- 
man ARFI in mammalian cells leads to inhibition of  both the 
secretory and endocytic pathways for membrane transport, 
and results in marked changes in the morphology of several 
subcellular organeiles. In ceils expressing mutant ARF1 pro- 
tein, the time required to see effects on protein secretion, 
morphological changes in the ER and Golgi, and functional 
effects on endocytosis all paralleled the time required for in- 
duction of ARFI antigen as determined by immunoblot anal- 
ysis. The failure of wild-type ARFI, expressed at higher lev- 
els than the mutant, to cause these changes argues against 
any nonspecific consequences resulting from the overexpres- 
sion of human ARF1. Moreover, changes in gene expression 
as a result of incubation of ceils with the inducer, interferon, 
did not cause the changes documented here. These results 
extend previous observations made in cell-free systems and 
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Figure 6.  Effect  of ARF1 expression on fluid-phase endocytosis. 
ZC1-0B (vector control,  triangles), ZCI-IA (wild-type ARF1, 
squares), and ZC1-3B (mutant ARF1, circles) cells were incubated 
with interferon for up to 24 h, then analyzed for their ability to take 
up the fluid phase marker, HRP, as descdbod in Materials and 
Methods. The data is expressed  as the percent of  peroxidase  activity 
taken up in the presence of interferon compared to the absence of 
interferon. The 100% values were 106 4- 5.5, 106 ±  5.1, and 73 
+  1.5  A~0  U/rag protein for  ZC1-0B, ZCMA,  and  ZC1-3B, 
respectively. Each point is the average of triplicate determinations 
of uptake. This experiment was repeated four times with nearly 
identical results. 
strongly suggest a central role for ARF proteins as regulators 
of intracellular vesicle traffic at several steps. 
The  most dramatic  effects  of [Q71L]ARF1  expression, 
visible by both light and electron microscopy, are on the 
Golgi apparatus. This was not unexpected as ARF proteins 
have been previously localized to the Golgi in a number of 
cell types (Stearns et al.,  1990b;  Donaldson et al.,  1991), 
and have been functionally linked to Golgi function both by 
genetic (Stearns et al., 1990b) and biochemical tests (Sera- 
fini et al.,  1991; Kahn et al.,  1992).  Large changes in the 
morphology and apparent volume of this compartment ac- 
company the expression of mutant but not wild-type ARF1. 
These changes were observed with markers of Golgi lipids 
(NBD-ceramide; Fig. 4 B), lumenal proteins (mannosidase 
II; Fig. 4 F), and cytosolic-associated proteins (/3-COP [not 
shown] and ARF, Fig. 3 F), indicating that the organelle it- 
self has undergone gross morphological changes and not 
simple redistribution of a single marker. EM reveals the loss 
of Golgi lamellae, replaced by a profusion of vesicles. Al- 
though quantitative analyses of membrane surface to volume 
ratios were not performed in these studies, it is obvious that 
the volume of the Golgi (and ER) lumen is expanded enor- 
mously in cells expressing mutant ARE 
What is the relationship between the vesicles produced in 
induced ZC1-3B cells and the previously described (Orci et 
al., 1986; Malhotra et al., 1989) Golgi-derived, COP-coated 
vesicles? Interestingly, we did not observe an accumulation 
of coated vesicles, as might be predicted if the ARF1 mutant 
simply cannot hydrolyze GTE It is not clear if either the 
vesicles observed with mutant ARF1 expression in live cells 
or the Golgi-derived coated vesicles, observed after GTP3,S 
treatment of broken cell preparations,  represent an inter- 
The Journal  of  Cell  Biology,  Volume 124,  1994  296 Figure 7. [Q71L]ARF1 expression attenuates the effects of brefeldin  A on coatomer binding  to the Golgi apparatus. ZCI-IA (wild-type ARFI) 
and ZC1-3B (mutant ARFI) cells were grown in the presence of interferon for 18 h before the addition of BFA (10/~M) for 0 (untreated), 
1, 2, or 5 min (as indicated) at 37°C. The cells were then fixed and stained by indirect immunofluorescence  using the anti-E-COP antibody, 
as described in Materials and Methods. 
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and result from gross changes in Golgi morphology and in- 
tegrity. Nevertheless, these data from live cells expressing 
mutant ARF1 provide new information since they were ob- 
tained without the use of GTP~S, which can activate more 
than one GTP-binding protein. The vesicles shown in Fig. 
5 are larger and less uniform in size than the 75-110-nm di- 
ameter Golgi-derived vesicles obtained by incubating Golgi 
preparations in GTP~/S (Serafini etal., 1991). However, the 
vesicles seen in Fig. 5 are from cells maximally induced for 
the expression of  mutant ARF1. We cannot exclude the possi- 
bility of smaller vesicles fusing to form these larger struc- 
tures. We consider it unlikely that the vesiculated Golgi seen 
in these cells result from an inability to arrest or regulate the 
normal budding process. According to at least one model for 
ARF action in vesicle transport (Serafini etal.,  1991), the 
presence of ARF and associated coat proteins helps target 
the vesicle and is incompatible with fusion. Thus, fusion of 
Golgi-derived, COP-coated vesicles to form the larger vesic- 
ulated Golgi remnants seen in Fig. 5 appears unlikely. We 
believe  a  more  likely  explanation  for  the  observations 
reported here is that a properly cycling ARF1 is required for 
the integrity of the Golgi apparatus itself. We lack detailed 
information regarding molecular mechanisms for such a role 
but they may include a structural role in coordinating the as- 
sembly or stability of a  multi-subunit complex such as a 
coatomer, or as a regulator of the volume of a membrane- 
bounded space, perhaps by affecting ion movements, or of 
intracellular membrane lipids (see below). 
The consequences of the expression of [Q71L]ARF1 on the 
morphology of the  ER  are  also  dramatic.  Two previous 
studies (Stearns etal.,  1990b;  Balch etal,,  1992) provide 
data supporting a role for ARF in ER function or ER-Golgi 
traffic. In yeast cells made deficient in ARF, the secreted pro- 
tein  invertase  accumulated  in  a  core-glycosylated form, 
similar  to  that  seen  in  the  sec18-1  mutant,  blocked  for 
ER-Golgi transport (Stearns etal., 1990b).  Such data indi- 
cate a lack of  processing of  the invertase, which normally oc- 
curs  in  the  Golgi  compartment,  and,  thus  suggests,  an 
ER-Golgi blockade. Similarly, the in vitro transport of  vesic- 
ular stomatitis virus G protein from ER to Golgi was po- 
tently and specifically inhibited by an NH2-terminal inhibi- 
tory ARF1 peptide (Balch et al,,  1992).  Although no data 
on the functional integrity of the ER or quantitation of sur- 
face to volume ratios were analyzed in these studies, it is 
clear that the lumen of the ER is substantially enlarged and 
likely that the function of  this compartment is compromised. 
Indeed, inability of newly synthesized protein or membrane 
to exit the ER may be responsible for the enlargement of the 
ER lumen and contribute to loss of Golgi lamellae integrity. 
It is likely that a  common molecular mechanism will be 
found to explain the expansion in the lumenal volume of  both 
the ER and the Golgi compartments. 
In contrast to the dramatic changes observed in the ER and 
Golgi compartments with [Q71L]ARF1 expression, we were 
unable to detect gross changes in the morphology of the en- 
docytic compartment. No gross changes in the morphology 
of the early endocytic compartment were observed by visual- 
ization of fluorescent markers (data not shown). However, it 
is clear from our functional studies (shown in Fig. 6) that up- 
take of HRP, an indicator of fluid phase endocytosis, is in- 
hibited by expression of the mutant ARF1 protein. Studies of 
in vitro endosome-endosome fusion suggested that activated 
(GTP bound) ARF is required for endosome fusion, but in- 
hibits when the active protein is in excess (Lenhard etal., 
1992). Based on these observations we speculate that the in- 
duced ZC1-3B cells likely contain endosomes that cannot 
fuse, with the concomitant sequestration of critical compo- 
nents required for endosome formation or fusion. Another 
possibility is that the inhibition of Golgi function prevents 
exocytic delivery of new membrane required for prolonged 
endocytic activity. 
We are currently considering two general models to ex- 
plain the diverse changes accompanying expression of a sin- 
gle ARF mutant in cells that also express several other native 
ARF proteins.  In  one model we  hypothesize that ARF1 
specifically regulates multiple steps in the endocytic and exo- 
cytic pathways and that each of the phenotypes identified in 
our studies result from mutant ARFI acting at sites where 
the wild-type protein normally functions. This model leaves 
open the role for the other ARF proteins (ARF3-6) in the 
cell. In the alternative model, we hypothesize that [Q71L]- 
ARF1  can functionally interact with a  regulatory protein 
shared by more than one ARF isoform and in this way affect 
vesicle traffic at steps normally regulated by distinct ARF 
proteins.  Such regulatory proteins may include the BFA- 
sensitive AAP or an ARF GTPase-activating protein (ARF 
GAP). These models are currently being tested by the regu- 
lated expression of different ARF isoforms and through bio- 
chemical tests of mutant ARF1 proteins in AAP and ARF 
GAP assays, respectively. 
Mutation of the glutamine in the consensus GTP-binding 
domain, DXXGO~ results in a dominant activated allele of a 
number of regulatory GTP-binding proteins, but decreased 
GTP hydrolysis can apparently arise by two distinct mecha- 
nisms. The intrinsic GTP hydrolytic rate of [Q227L]Gs~ is 
reduced ~100-fold resulting in a prolonged activated state 
(Graziano etal., 1989; Masters etal., 1989), while the criti- 
cal effect of [Q61Llras is more likely explained by its higher 
('~50-fold) affinity for GTPase-activating protein (GAP) and 
failure to hydrolyze GTP when bound to GAP (Vogel et al., 
1988; Gideon etal., 1992).  Preliminary evidence indicates 
that ARFs are more ras-like than G  protein-like in that a 
specific GAP activity has been identified which is potently 
inhibited by the [Q71L] mutant (Randazzo, P. A., and R. A. 
Kahn, unpublished observation). Other data can also be in- 
terpreted as indirect support for the hypothesis that the domi- 
nant effects of [Q71L]ARF1 result from its increased level 
of activation and/or inhibition of ARF GAP activity. First, 
the purified human ARF1 protein has no detectable intrinsic 
GTPase activity (Kahn and Gilman,  1986;  Weiss et al., 
1989) and thus lowering this rate is unlikely to be of  biological 
significance. Second, the corresponding mutation in S. cere- 
visiae ARF1 ([Q71L]ARF1) is a dominant lethal allele but the 
purified recombinant protein has nearly the same intrinsic 
GTPase activity as the wild-type protein (Rulka, C.,  and 
R. A. Kahn, manuscript in preparation). Third, analysis of 
bound nucleotides on immunoprecipitated [Q71L]ARF1 in 
yeast revealed most of the ARF1 protein to have GTP bound 
while wild-type protein analyzed the same way had exclu- 
sively GDP bound (Zhang, C., unpublished observation). 
We have been unable to document the nucleotides bound to 
ARF proteins obtained by immunoprecipitation from cul- 
tured mammalian cells. Taken together these data make it 
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activated  form of ARF which inhibits ARF GAP activity. 
Studies of the effects of BFA on cultured cells and enriched 
membrane fractions have confirmed that ARF proteins func- 
tion through the regulated cycling of activated  (GTP bound) 
and  inactive  (GDP bound)  proteins which are  membrane 
associated  or  soluble,  respectively.  The  finding  that  BFA 
cannot reverse the activated  state but rather, blocks the acti- 
vation step led to the identification by three different labora- 
tories of the BFA-  and trypsin-sensitive  AAP.  It was pre- 
dicted, therefore, that expression of a dominant activating 
allele of ARF1  may  appear  antagonistic  to the  actions  of 
BFA.  Indeed, as shown in Fig.  7, the actions of BFA were 
markedly attenuated  or delayed by the prior expression of 
mutant ARF1.  In addition, in contrast to the effects of BFA 
on cells in culture,  expression of [QT1L]ARF1 resulted in 
altered morphology but maintained distinct ER and Golgi 
compartments (see Fig. 4, F and H). These results further 
indicate that the mutant ARF1 is not cycling, but is arrested 
in the activated, membrane-associated form. We would pre- 
dict that expression of a dominant inactivating  allele of ARF 
would mimic the effects of BFA  and cause the retrograde 
movement of Golgi elements back toward  the ER. 
The expression of dominant alleles of members of the ARF 
family under inducible control will likely provide valuable 
information  regarding  the  functions  of these  proteins  as 
regulators of distinct steps in the secretory pathway and other 
cellular processes. The sensitivity of a variety of vesicle bud- 
ding/fusion reactions to ARF proteins suggests that a com- 
mon molecular mechanism will ultimately be found. The re- 
cent  purification  of ARF  proteins  as  the  cytosolic  factor 
which confers GTP'rS sensitivity to phospholipase D activ- 
ity (Brown et al.,  1993) offers an attractive  explanation for 
the actions of ARF on vesicle formation or fusion. Modula- 
tion of bilayer lipids by an ARF-regulated phospholipase D 
may also explain the sensitivity of ARF activities to different 
lipids (Kahn et al., 1986). Specific tests of this and other hy- 
potheses are now possible with these and related  cell lines. 
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